PharmGen Science, Inc.

KSE 004720.KS

PharmGen Science, Inc. EBITDA for the year ending December 31, 2023: USD 10.27 M

PharmGen Science, Inc. EBITDA is USD 10.27 M for the year ending December 31, 2023, a 20.57% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

PharmGen Science, Inc. EBITDA for the year ending December 31, 2022 was USD 8.52 M, a 666.67% change year over year.
PharmGen Science, Inc. EBITDA for the year ending December 31, 2021 was USD -1.50 M, a -254.86% change year over year.
PharmGen Science, Inc. EBITDA for the year ending December 31, 2020 was USD 970.70 K, a -68.00% change year over year.
PharmGen Science, Inc. EBITDA for the year ending December 31, 2019 was USD 3.03 M, a -45.02% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

KSE: 004720.KS

PharmGen Science, Inc.

CEO	Lee Seung-Yeol
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	50, Jeyakgongdan 2-gil
Employees	248
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.

Key trends

Past 5 years